Ironjustic
Thu, Nov-23-06, 06:15
<<snip>> these drugs unexpectedly exert powerful inhibition on
both the inflammation and coagulation systems <<snip>>
Microcirculation. 2006 Sep;13(6):489-97. Links Robust vascular
protective effect of hydroxamic acid derivatives in a sickle
mouse model of inflammation.Kaul DK, Kollander R, Mahaseth H,
Liu XD, Solovey A, Belcher J, Kelm RJ Jr, Vercellotti GM,
Hebbel RP. Department of Medicine, Albert Einstein College of
Medicine, New York, Bronx, USA.
OBJECTIVE: Clinically, the vascular pathobiology of human
sickle cell disease includes an abnormal state of chronic
inflammation and activation of the coagulation system. Since
these biologies likely underlie development of vascular
disease in sickle subjects, they offer attractive targets for
novel therapeutics. Similar findings characterize the sickle
transgenic mouse, which therefore provides a clinically
relevant inflammation model. METHOD: The authors tested two
polyhydroxyphenyl hydroxamic acid derivatives, didox and
trimidox, in sickle transgenic mice. Animals were examined by
intravital microscopy (cremaster muscle and dorsal skin fold
preparations) and by histochemistry before and after transient
exposure to hypoxia, with versus without preadministration of
study drug. Previous studies have validated the application of
hypoxia/reoxygenation to sickle transgenic mice as a
disease-relevant model. RESULTS: Animals pretreated with these
agents exhibited marked improvements in leukocyte/ endothelial
interaction, hemodynamics and vascular stasis, and endothelial
tissue factor expression. Thus, these drugs unexpectedly exert
powerful inhibition on both the inflammation and coagulation
systems. CONCLUSIONS: Each of these changes is expected to be
therapeutically beneficial in systemic inflammatory disease in
general, and in sickle disease in particular. Thus, these
novel compounds offer the advantage of having multiple
therapeutic benefits in a single agent.
PMID: 16864415 [PubMed - indexed for MEDLINE]
--------------------------------------------------------------
------------------------
http://scientific.thomson.com/free/meetingpreviews/2003/81775-
95/
<<snip>> didox and trimidox possess free radical scavenging
and iron chelating properties <<snip>>
Who loves ya. Tom
Jesus Was A Vegetarian! http://jesuswasavegetarian.7h.com
Man Is A Herbivore! http://tinyurl.com/a3cc3
DEAD PEOPLE WALKING http://tinyurl.com/zk9fk
both the inflammation and coagulation systems <<snip>>
Microcirculation. 2006 Sep;13(6):489-97. Links Robust vascular
protective effect of hydroxamic acid derivatives in a sickle
mouse model of inflammation.Kaul DK, Kollander R, Mahaseth H,
Liu XD, Solovey A, Belcher J, Kelm RJ Jr, Vercellotti GM,
Hebbel RP. Department of Medicine, Albert Einstein College of
Medicine, New York, Bronx, USA.
OBJECTIVE: Clinically, the vascular pathobiology of human
sickle cell disease includes an abnormal state of chronic
inflammation and activation of the coagulation system. Since
these biologies likely underlie development of vascular
disease in sickle subjects, they offer attractive targets for
novel therapeutics. Similar findings characterize the sickle
transgenic mouse, which therefore provides a clinically
relevant inflammation model. METHOD: The authors tested two
polyhydroxyphenyl hydroxamic acid derivatives, didox and
trimidox, in sickle transgenic mice. Animals were examined by
intravital microscopy (cremaster muscle and dorsal skin fold
preparations) and by histochemistry before and after transient
exposure to hypoxia, with versus without preadministration of
study drug. Previous studies have validated the application of
hypoxia/reoxygenation to sickle transgenic mice as a
disease-relevant model. RESULTS: Animals pretreated with these
agents exhibited marked improvements in leukocyte/ endothelial
interaction, hemodynamics and vascular stasis, and endothelial
tissue factor expression. Thus, these drugs unexpectedly exert
powerful inhibition on both the inflammation and coagulation
systems. CONCLUSIONS: Each of these changes is expected to be
therapeutically beneficial in systemic inflammatory disease in
general, and in sickle disease in particular. Thus, these
novel compounds offer the advantage of having multiple
therapeutic benefits in a single agent.
PMID: 16864415 [PubMed - indexed for MEDLINE]
--------------------------------------------------------------
------------------------
http://scientific.thomson.com/free/meetingpreviews/2003/81775-
95/
<<snip>> didox and trimidox possess free radical scavenging
and iron chelating properties <<snip>>
Who loves ya. Tom
Jesus Was A Vegetarian! http://jesuswasavegetarian.7h.com
Man Is A Herbivore! http://tinyurl.com/a3cc3
DEAD PEOPLE WALKING http://tinyurl.com/zk9fk